SB Transposon Platform for Non-Viral CAR-T Development

Online Inquiry

Background Service Technical Specifications Workflow Highlights FAQs Contact

While conventional CAR-T therapies offer transformative potential, their development remains severely constrained by the high production costs, limited payload capacity, and complex safety profiles of viral vectors. To overcome these hurdles, we offer our advanced SB Transposon Platform for Non-Viral CAR-T Development. Our comprehensive service spans from custom transposon vector design and optimization to highly efficient in vitro T cell engineering and rigorous functional validation. By leveraging our scalable and cost-effective system, we empower you to rapidly accelerate pre-clinical pipelines, enhance therapeutic safety, and successfully advance novel immunotherapies toward clinical application.

Introduction

The Sleeping Beauty (SB) transposon system comprises a synthetic DNA transposase capable of precisely integrating therapeutic transgenes into vertebrate genomes, thereby overcoming the limitations of persistent episomal expression. SB mediates cut-and-paste transposition via a bipartite recognition mechanism, wherein the transposase binds to inverted terminal repeats (ITRs) flanking the gene of interest, excises the cassette from a donor plasmid, and integrates it into TA-dinucleotide-rich chromosomal loci with a defined, yet relatively random, genomic distribution.

Fig.1 The structural architecture of the Sleeping Beauty transposable element comprises specific conserved domains. (OA Literature) Fig.1 The Sleeping Beauty transposable element is characterized by distinct structural features. ¹

Our Service

Our SB Transposon Platform offers a non-viral solution for CAR-T development, overcoming the cost, safety, and payload constraints of traditional viral systems. By enabling stable transgene integration and sustained CAR expression, it streamlines T cell engineering from design through validation. We deliver scalable, cost-effective manufacturing and accelerated preclinical timelines, empowering you to advance safer immunotherapies to the clinic with confidence.

Technical Specifications

This high-performance transposition system, belonging to the Tc1/mariner superfamily. Optimizing non-viral CAR-T development, it combines an exceptional cargo capacity with highly efficient human cell integration and a safer, nearly random insertion profile.

Featured services of SB transposon platform for non-viral CAR-T development at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

T cells or peripheral blood mononuclear cells (PBMCs) derived from the patient or a healthy donor.
Target gene sequence information.

Key Steps:

Workflow of SB transposon platform for non-viral CAR-T development at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Cryopreserved CAR-T cell product.
Quality control data.

Key Advantages

High Cost-Effectiveness: Utilizing mature DNA plasmid manufacturing simplifies purification and accelerates research cycles, significantly reducing raw material costs and development timelines compared to viral vectors.
Superior Safety Profile: The platform mitigates insertional mutagenesis risks through a near-random genomic integration profile that avoids gene-dense regions, while minimizing adverse immune reactions due to its non-viral nature.
Large Cargo Capacity: Unconstrained by viral capsid size limitations, the platform accommodates larger gene inserts, facilitating the delivery of complex multi-targeted or multifunctional CAR circuits.

FAQ

Q1: How does the genomic integration profile of the SB transposon differ from lentiviral vectors, and what are the safety implications?

A1: Unlike lentiviruses that preferentially target transcriptionally active regions and risk oncogene activation, the SB system utilizes a "cut-and-paste" mechanism targeting TA dinucleotides near-randomly. Avoiding gene-dense areas significantly minimizes insertional mutagenesis and T cell malignant transformation, delivering a superior clinical safety profile for cell therapy development.

Q2: What is the cargo capacity limit of the SB transposon platform, and does it support multi-targeted CAR engineering?

A2: While lentiviral vectors are constrained to under 9 kb, the SB platform efficiently accommodates inserts exceeding 10-11 kb without compromising integration efficiency. This expanded capacity easily supports complex, multi-targeted CAR designs and the co-expression of immunomodulators like IL-15 or PD-1 checkpoints to remodel the solid tumor microenvironment.

Why Choose Us?

Our SB Transposon Platform delivers a highly efficient, cost-effective, and scalable non-viral alternative for CAR-T cell manufacturing. By ensuring high-fidelity gene integration, robust therapeutic expression, and minimized immunogenicity, we streamline the path from discovery to clinical translation.

Customer Reviews

"Switching to this SB Transposon Platform revolutionized our pipeline. We completely bypassed the lengthy and expensive viral vector manufacturing bottlenecks. The platform delivered exceptionally high integration efficiency and stable CAR expression, allowing us to accelerate our preclinical timelines by months." Dr. A* K*.

"Safety and scalability were our primary concerns. This platform's non-viral approach significantly reduced the risk of insertional mutagenesis while maintaining a highly favorable safety profile. The cell viability post-transfection was outstanding, ensuring robust expansion for our downstream applications." Prof. E* D*.

How to contact us?

Seeking to overcome the bottlenecks of viral-based systems? We are your dedicated partner in advancing non-viral CAR-T platforms. Our scientists provide discrete consultations, rigorous protocol reviews, and bespoke project planning. Get in touch—let us help you navigate the path from discovery to the clinic with confidence and agility.

Reference

Ochmann, Matthias T, and Zoltán Ivics. "Jumping Ahead with Sleeping Beauty: Mechanistic Insights into Cut-and-Paste Transposition." Viruses vol. 13,1 76. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/v13010076.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.